Home

home-bloc1

Our vocation

GlioCure aims to give back hope to patients suffering from glial diseases, and in particular to patients with hard-to-treat brain tumours, such as gliobastoma.
To achieve this goal, GlioCure has brought  together a scientific and medical advisory board of international experts with all the necessary skills for translational development to treat and/or cure glial diseases.
Our first product, GC01, is a new generation anti-tumor peptide, which is currently in the final stages of non-regulatory preclinical development for the treatment of glioblastoma.

Learn more
2

patents
families

2

on-going
R&D programs

800000

in pre-seed
fundings

home-bloc2

News

June 21st 2019 : GlioCure receives the "Label of Excellence" from the European Commission under the H2020 Instrument PME phase 1 scheme for its project:
Game-changing anti-mitotic peptide for the treatment/cure of glioblastoma and other aggressive cancers over-expressing βIII-tubulin

Seal of Excellence

Learn more
home-bloc3

Our science

GlioCure offers a complete translational solution to transform molecules of interest in the field of neuro-oncology into clinical drug candidates.

Learn more
home-bloc4

Our products

With GC01, its first molecule of interest, GlioCure targets several neuro-oncology indications with urgent unmet medical needs, such as glioblastoma and secondary brain metastases.

Learn more

Patients

Glioblastoma belongs to the family of gliomas, brain tumors that affect the glial cells. These cells form the environment of neurons with a role of support and protection of the nervous tissue and represent half of the cerebral volume.

Learn more
home-bloc5

Media

Find here our press releases, our main media coverage and the events in which we participate.

Learn more
home-bloc6